Colloidal Nanocarriers for Dermatological Diseases Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (10 March 2024) | Viewed by 8389
Special Issue Editor
Interests: lipid nanocarriers; hydrogels; wound healing; skin disorders; skin regeneration; drug release kinetics; design of experiments (DOE); molecular dynamics (MD)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Designing novel drug delivery systems that can accurately and safely deliver a drug to a target in a controlled manner with maximum therapeutic effect continues to be the main focus of pharmaceutical and medical research. In recent years, there has been significant development in nanomedicine and nanotechnology for the treatment of skin disorders, including wound healing. In particular, colloidal nanocarriers (nanoemulsions, nanocapsules, lipid nanoparticles, nanoemulgels, etc.) have gained much attention due to their biocompatibility, biodegradability, low toxicity, and ability to encapsulate hydrophobic active substances that are difficult to formulate, thereby increasing their bioavailability. Prolonged and controlled drug release, characteristic of colloidal nanocarriers, allows us to reduce the required amount of active substances and, consequently, eliminate potential side effects. Thanks to these properties, they can be used as effective drug carriers for skin diseases such as local inflammation, bacterial infections, cancer, psoriasis, atopic/contact dermatitis, rosacea and acne.
Dr. Małgorzata Miastkowska
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoemulsions
- nanocapsules
- lipid nanoparticles
- nanoemulgels
- skin diseases
- psoriasis
- atopic dermatisis
- skin regeneration
- controlled drug release
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.